Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9604058 | 0.80 | MAPT (0.44) | APPPTGS1KCNH2MAT2ARELA | |
| SCHEMBL13636751 | 0.79 | NFE2L2 (0.76) | NFE2L2APPPTGS1PTGS2KCNH2 | |
| SCHEMBL14526427 | 0.78 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1APP | |
| SCHEMBL13636778 | 0.77 | NFE2L2 (0.49) | NFE2L2CYP1A1CYP1B1APPPTGS1 | |
| SCHEMBL13636756 | 0.76 | NFE2L2 (0.47) | NFE2L2CYP1A1CYP1A2CYP1B1APP | |
| SCHEMBL12128483 | 0.75 | MAPT (0.40) | CYP1A2APPPTGS1KCNH2MAT2A | |
| SCHEMBL12128520 | 0.75 | MAPT (0.40) | CYP1A2APPPTGS1KCNH2MAT2A | |
| SCHEMBL13636784 | 0.75 | PTGS1 (0.42) | CYP1A1CYP1A2CYP1B1APPPTGS1 | |
| SCHEMBL13636781 | 0.74 | APP (0.46) | NFE2L2APPKCNH2MAT2ARELA | |
| SCHEMBL13636783 | 0.73 | NFE2L2 (0.43) | NFE2L2APPPTGS1KCNH2MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785001-B2 | Organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8304095-B2 | Organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20080297037-A1 | Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20080272693-A1 | Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080272693-A1 | Organic Electroluminescent Devices | EML4, MT-ND4L, EPCAM | NFE2L2 423/4885CYP1A1 3861/4885CYP1A2 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.